A large-scale international study published in The Lancet Neurology reveals that the genetic drivers of Parkinson’s disease vary significantly across different ancestry groups. Researchers analyzed data from nearly 100,000 participants through the Global Parkinson’s Genetics Program to map how specific mutations influence disease risk in diverse populations.
The findings show that while certain genes like GBA1 remain important across all groups, the specific variants within those genes differ by ancestry. For example, some variants common in populations of African descent are rare in European populations. This underscores the limitations of research that historically focused on a single demographic.
This work is critical for the development of precision medicine. As pharmaceutical companies create therapies that target specific genes like GBA1 and LRRK2, the clinical success of these treatments depends on understanding how these genes function across global populations. If researchers ignore this genetic diversity, they risk creating treatments that are ineffective for large portions of the world.
Nearly 30 percent of the study participants came from historically underrepresented groups. The researchers state that this diversity is not just a matter of equity but a scientific necessity for successful medical advancement. Moving forward, the inclusion of diverse genetic data will determine the effectiveness and accessibility of new Parkinson’s therapies for patients everywhere.